Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

U.S. President Donald Trump signed a spending package into law Tuesday that reauthorizes the FDA’s previously stalled rare ...

Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to ...

AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...